Pancreatic Cancer Research

ResearcherThe Affiliated Yongchuan Hospital of Chongqing Medical UniversityActive in the last 2 years

Chengyou Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1977-6362; OpenAlex author ID A5101612588. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  2. CT-based habitat analysis combined with multi-channel deep learning for predicting early recurrence after pancreatic cancer resection: a multicenter study. Co-author DOI 10.1186/s12967-026-08370-0↗
  3. Global trends and future predictions of pancreatic cancer incidence and mortality from 1990 to 2030: A comparative analysis of China, Korea, Japan, and the USA. Last author DOI 10.1371/journal.pone.0337181↗
  4. Comparison of laparoscopic versus open radical antegrade modular pancreatosplenectomy for pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ijsu.2022.106676↗
  5. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Co-author DOI 10.1042/bsr20204301↗
  6. GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.11423↗
  7. Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in Chi… Last author DOI 10.1186/s12957-015-0608-4↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ke Xu · 2 shared papers, 2021 · strength 0.31
  2. Kun Huang · 1 shared paper, 2025 · strength 0.30
  3. Yu You · 1 shared paper, 2026 · strength 0.27
  4. Jinzheng Li · 1 shared paper, 2026 · strength 0.27
  5. Jialun Peng · 1 shared paper, 2026 · strength 0.27
  6. Yanqiao Zhang · 1 shared paper, 2026 · strength 0.19
  7. Xiuchao Wang · 1 shared paper, 2026 · strength 0.19
  8. Song Gao · 1 shared paper, 2026 · strength 0.19
  9. Chuntao Gao · 1 shared paper, 2026 · strength 0.19
  10. Tiansuo Zhao · 1 shared paper, 2026 · strength 0.19
  11. Zhihua Li · 1 shared paper, 2026 · strength 0.19
  12. Xiujuan Qu · 1 shared paper, 2026 · strength 0.19
  13. Jihui Hao · 1 shared paper, 2026 · strength 0.19
  14. Rui Liu · 1 shared paper, 2026 · strength 0.19
  15. Xianglin Yuan · 1 shared paper, 2026 · strength 0.19
  16. Bo Liu · 1 shared paper, 2021 · strength 0.17
  17. Wei Tang · 1 shared paper, 2022 · strength 0.16
  18. Yufei Zhao · 1 shared paper, 2022 · strength 0.16
  19. Jianguo Qiu · 1 shared paper, 2022 · strength 0.16
  20. Tao Ren · 1 shared paper, 2021 · strength 0.14
  21. Wei Zhou · 1 shared paper, 2021 · strength 0.14
  22. Bo Liu · 1 shared paper, 2021 · strength 0.14
  23. Rui Liao · 1 shared paper, 2015 · strength 0.06
  24. Ping Cheong Huang · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.